1. Home
  2. BTGO vs ALLO Comparison

BTGO vs ALLO Comparison

Compare BTGO & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BitGo Holdings Inc. Class A Common Stock

BTGO

BitGo Holdings Inc. Class A Common Stock

N/A

Current Price

$3.40

Market Cap

496.1M

Sector

Finance

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$0.63

Market Cap

452.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTGO
ALLO
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
496.1M
452.6M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
BTGO
ALLO
Price
$3.40
$0.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
12
Target Price
$8.88
★ $9.00
AVG Volume (30 Days)
1.1M
★ 11.4M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 34.09
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.14
$180.53
P/E Ratio
$10.81
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.48
$0.65
52 Week High
$15.30
$4.46

Technical Indicators

Market Signals
Indicator
BTGO
ALLO
Relative Strength Index (RSI) 24.00 17.76
Support Level N/A N/A
Resistance Level $5.72 $2.22
Average True Range (ATR) 0.39 0.09
MACD -0.08 -0.03
Stochastic Oscillator 2.60 0.05

Price Performance

Historical Comparison
BTGO
ALLO

About BTGO BitGo Holdings Inc. Class A Common Stock

BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: